Sep 2006;52(9):877-85
For instance, SUSTAIN 6 indicated a reduction in major cardiovascular events among patients treated with semaglutide
Obesity and overweight, which are common in patients with DM2, are a factors that favor the development/progression of CKD through both direct and indirect effects.69 Although the precise mechanisms the association between obesity and CKD are not totally defined it has been proposed that hypertension, glomerular hyperfiltration, hyperglycemia, lipid toxicity, inflammation or the role of adipose tissue and its adipokines are involved.70 Weight reduction by bariatric surgery, pharmacological treatment or dietary measures are associated with a nephroprotective effect,7173 so that weight reduction is a fundamental objective in the nephroprotection of patients with DKD
However, when selecting a course of treatment, it is important to take into account the frequency of gastrointestinal adverse events (AEs)
That's an unusually efficient tool for metabolic investigation
The exact mechanism for topiramates weight effect is still partly understood, but the clinical results are well documented
